CLEVELAND, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) will release its year-end 2016
financial results at approximately 4:00 PM Eastern Time on Thursday, March 9, 2017, and will host a conference call shortly
thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William
(B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:
Date |
March
9, 2017 |
Time |
4:30 p.m. (Eastern
Time) |
Telephone access: US and Canada |
(800)
273-1254 |
Telephone access: International |
(973)
638-3440 |
Access
code |
73151585 |
Live
webcast |
www.athersys.com
under Investors section
|
A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM
Eastern Time on March 23, 2017 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or
from abroad (404) 537-3406, and entering access code 73151585.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic
product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem®
cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the
neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this
potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical
and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More
information is available at www.athersys.com.
ATHX-G
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 bjlehmann@athersys.com David Schull Russo Partners, LLC 12 West 27th Street, 4th Floor New York, NY 10001 Tel: (212) 845-4271 David.schull@russopartnersllc.com